Modified IGF1 polypeptides with increased stability and potency
US7355018B2 · kind B2 · utility
33Cited by
3References
4Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Sep 30, 2004 |
| Grant date | Apr 8, 2008 |
| Priority date | — |
| Expiry date | Oct 10, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/74
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A targeting fusion protein comprising a component that comprises a (i) ligand or derivative or fragment thereof that binds a pre-selected target surface protein, such as a receptor, and (ii) an active agent or therapeutic agent(s), and further optionally (iii) a multimerizing component and/or (iv) a signal sequence. In a preferred embodiment, the targeting fusion polypeptide targets muscle and is useful to treat a muscle-related disease or condition, such as muscle atrophy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.